Nab-placlitaxel

Phase 2Small molecule

BioNTech

Nab-placlitaxel is one of 30 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Locally Advanced Breast CancerActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Locally Advanced Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Adenocard

Astellas

Preclinical

1 5

Nab-placlitaxel

BioNTech

Phase 2

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Active, not recruiting

Locally Advanced Breast Cancer

NCT06449222

Clinical

Trials by Indication[1]

Locally Advanced Breast Cancer1 trial

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449222·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nab-placlitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nab-placlitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nab-placlitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BioNTech

Nab-placlitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Locally Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News